Showing results (1-10 of 87) with videos related to
Sort By:
Pageof 9
Oncotarget|February 25, 2016
APG101 efficiently rescues erythropoiesis in lower risk myelodysplastic syndromes with severe impairment of hematopoiesisAnna Raimbault, Cecile Pierre-Eugene, Alexandra Rouquette, et al.Cytometry. Part B, Clinical Cytometry|April 10, 2019
The fraction of CD117/c-KIT-expressing erythroid precursors predicts ESA response in low-risk myelodysplastic syndromesAnna Raimbault, Raphael Itzykson, Lise Willems, et al.Cytometry. Part B, Clinical Cytometry|September 10, 2019
Phenotypic landscape of granulocytes and monocytes by multiparametric flow cytometry: A prospective study of a 1-tube panel strategy for diagnosis and prognosis of patients with MDSSylvain Barreau, Alexa S Green, Charles Dussiau, et al.Diagnostics (Basel, Switzerland)|July 27, 2022
Diagnosis of Myelodysplastic Syndromes: From Immunological Observations to Clinical ApplicationsYannick Simoni, Nicolas ChapuisBulletin Du Cancer|July 9, 2023
[Pathophysiology of myelodysplastic syndromes]Michaela Fontenay, Ismael Boussaid, Nicolas ChapuisBritish Journal of Haematology|September 11, 2018
CD13 expression in B cell malignancies is a hallmark of plasmacytic differentiationAnna Raimbault, Sigrid Machherndl-Spandl, Raphaël Itzykson, et al.Medecine Sciences : M/S|September 7, 2021
[Ferroptosis and cancer: Physiopathological and therapeutic implications]Rudy Birsen, Eric Grignano, Nicolas Chapuis, et al.Frontiers in Oncology|October 12, 2020
From Iron Chelation to Overload as a Therapeutic Strategy to Induce Ferroptosis in Leukemic CellsEric Grignano, Rudy Birsen, Nicolas Chapuis, et al.Frontiers in Oncology|June 14, 2019
Rationale for Targeting Deregulated Metabolic Pathways as a Therapeutic Strategy in Acute Myeloid LeukemiaNicolas Chapuis, Laury Poulain, Rudy Birsen, et al.Current Oncology Reports|February 22, 2012
PI3K and mTOR signaling pathways in cancer: new data on targeted therapiesLise Willems, Jerome Tamburini, Nicolas Chapuis, et al.Pageof 9